ReviewCannabis and cannabinoid research2022
Quality Standards in State Programs Permitting Cannabis for Medical Uses.
Review in Cannabis and cannabinoid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Integrating Genetic and Biotechnological Approaches to Enhance High-CBD Cannabis sativa L. Cultivation for Medicinal Purposes.Molecular biotechnology · 2026Review
- Sanitation of medical cannabis flowers (Cannabis sativa L., flos): comparing current technologies and non-thermal plasma novelties from safety and quality perspectives.Journal of cannabis research · 2026Review
- Barriers to accessing prescribed medical cannabis: qualitative insights from people using non-prescribed cannabis for medicinal purposes in the Netherlands.Harm reduction journal · 2025Article
- Medicinal use of non-prescribed cannabis: a cross-sectional survey on patterns of use, motives for use, and treatment access in the Netherlands.Journal of cannabis research · 2025Article
- Regulatory trends of organophosphate and pyrethroid pesticides in cannabis and applications of the Comparative Toxicogenomics Database and Caenorhabditis elegans.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality?Journal of cannabis research · 2025Article
- The Elusive Truth of Cannabinoids for Rheumatic Pain.Current rheumatology reports · 2024Review
- Lessons for cannabinoid regulation from electronic nicotine delivery system product regulation.Health affairs scholar · 2024Article
- Fungal and mycotoxin contaminants in cannabis and hemp flowers: implications for consumer health and directions for further research.Frontiers in microbiology · 2023Review
- Medical Cannabis Received by Patients According to Qualifying Condition in a US State Cannabis Program: Product Choice, Dosing, and Age-Related Trends.Current therapeutic research, clinical and experimental · 2023Article
- Comparison of State-Level Regulations for Cannabis Contaminants and Implications for Public Health.Environmental health perspectives · 2022Article
- Investigation of microorganisms in cannabis after heating in a commercial vaporizer.Frontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Currently in the United States, there exists a patchwork of state-level laws and regulations surrounding cannabis use. Although cannabis (excluding hemp under the Agricultural Improvement Act of 2018, Public Law 115-334) is illegal at the federal level and is not FDA (U.S. Food and Drug Administration) approved for any indication, many states allow patients with qualifying conditions to register for their medical cannabis program (MCP). To better understand the quality of cannabis found in these programs, we collected laws, regulations, and guidance documents available on public state-run websites and compared them with current good manufacturing practices (CGMPs) applicable to finished drug products. CGMPs for human drugs contain minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging of a drug product to assure it is safe for use. Such a comparison will aid the development of consistent quality standards that could, in turn, improve the quality of a wide range of cannabis medical products in development that may be sold in the United States. States may likewise choose to have the cannabis and cannabis-derived products that fall within their MCP to follow quality-focused guidelines, such as those listed in CGMPs, to ensure the quality of these products and promote public health. This study further solidifies the need for standardized testing protocols and methodologies to keep consumers safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.